港股異動 | 康臣藥業盤中漲5% 股價創逾半年新高 機構料2022年收入有望維持兩位數增長
格隆匯2月9日丨康臣藥業(1681.HK)漲5.5%,報4.99港元,總市值40億港元,股價創2022年7月26日新高。康臣藥業是一家主要從事現代中成藥及醫用成像對比劑研發、生產及營銷的現代化製藥企業。方正證券表示,當前醫藥板塊估值處於歷史底部區域,建議短期可挖掘22Q4業績有望超預期個股,中長期看好中藥配方顆粒等疫後復甦的資產。興業證券認為,腎科和影像科有望成為公司的兩大支柱板塊,預計公司將不斷深耕現有產品市場和推動新產品上市,未來市場佔有率有望持續提升。國元國際預計,2022年全年收入有望維持兩位數的增長。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.